RMD News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

RM

Mkt Cap

$32.46B

Volume

1.27M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Is This the Right Time to Retain Resmed Stock in Your Portfolio?Resmed is divesting its MatrixCare business for $490 million to streamline its Residential Care Software segment and focus on higher-growth platforms. The company's Masks segment showed strong 13% revenue growth in fiscal 2026, driven by product innovation and improved compliance rates. However, macroeconomic pressures and intense competition pose operational risks.Zacks Investment Research · Sep 15, 2026

23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the SignsNASCAR driver Tyler Reddick announced his obstructive sleep apnea (OSA) diagnosis and partnership with Resmed to raise awareness about sleep apnea. After starting CPAP therapy in early 2026, Reddick won three consecutive NASCAR Cup Series races including the Daytona 500. The collaboration aims to educate the public about sleep apnea symptoms and encourage diagnosis, with Resmed branding appearing on Reddick's No. 45 Toyota at select races throughout the 2026 season.GlobeNewswire Inc. · Aug 25, 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 millionResMed has acquired Noctrix Health, a medical technology company specializing in wearable neuromodulation therapies for sleep and neurological conditions, for $340 million. This marks the first successful exit for Angelini Ventures, a corporate venture firm that invested in Noctrix during its $40 million Series C round in 2024. The acquisition will integrate Noctrix's FDA-authorized Nidra therapy for Restless Legs Syndrome into ResMed's broader sleep health ecosystem.Benzinga · Jun 3, 2026

9 Stocks That Could Defy the ’Sell in May and Go Away’ Trend This TimeDespite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.Investing.com · May 5, 2026

Sleep Apnea Devices (Therapeutic, Diagnostic) Market Report 2026-2034 Featuring Key Players - ResMed, Koninklijke Philips, and CarefusionThe global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicine adoption. However, challenges include high device costs, limited access in developing regions, and poor patient compliance with therapy.GlobeNewswire Inc. · Apr 29, 2026

Global Respiratory Care Devices Market to Grow at a Substantial Growth Rate of ~8% by 2034 | DelveInsightThe global respiratory care devices market is projected to grow from USD 24.3 billion in 2025 to USD 47.5 billion by 2034, at a CAGR of ~8%. Growth is driven by rising prevalence of chronic respiratory diseases (COPD, asthma, sleep apnea), increasing demand for home healthcare solutions, technological advancements, and post-COVID-19 awareness. North America leads with 41% market share, followed by Europe and Asia-Pacific.GlobeNewswire Inc. · Apr 22, 2026

3 Reasons Not to Sleep on ResMed StockResMed, a leader in CPAP machines and respiratory care devices, presents an attractive investment opportunity with 11% year-over-year revenue growth, expanding digital health capabilities across 140+ countries, and a forward P/E ratio of 22 (below its five-year average of 29). However, investors should be aware of potential headwinds including uncertain Medicare reimbursement rates and emerging alternative treatments.The Motley Fool · Mar 10, 2026

Anti-snoring Devices Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenue InsightsThe global anti-snoring devices market is expected to grow from $1.81 billion in 2025 to $3.36 billion by 2033, with an 8.04% CAGR. Growth drivers include rising obesity rates, increased awareness of health risks associated with snoring, technological innovations, and improved e-commerce accessibility. Major players like Philips, ResMed, and SomnoMed are leading the market with advanced solutions.GlobeNewswire Inc. · Feb 24, 2026

Analysts Maintain Bull Case On ResMed Despite Competition ConcernsResMed reported strong Q2 FY2026 results with adjusted earnings of $2.81 beating consensus of $2.72, and sales of $1.42 billion up 11% YoY. The company received FDA clearance for its AI-enabled Smart Comfort device and expects high single-digit revenue growth with double-digit EPS growth. Most analysts maintain positive ratings despite competition concerns, though stock declined 2.33% on the day.Benzinga · Jan 30, 2026

Mechanical Ventilators Market Size to Reach USD 6.91 Billion by 2035, Driven by Rising Respiratory Disease Burden and Expanding Critical Care Infrastructure – SNS InsiderThe global mechanical ventilators market is projected to grow from USD 4.04 billion in 2025 to USD 6.91 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by rising respiratory disease prevalence, expanding ICU infrastructure, and technological advancements including AI-enabled and portable ventilators. However, high device costs and limited healthcare funding remain significant market constraints.GlobeNewswire Inc. · Jan 29, 2026

RM

RMDResMed Inc.

RMD

Pay with—

Available Balance0.00

Your PositionYou don't own any RMD yet.

Related Tickers

Earnings

Dividends

Last · Aug 20Quarterly

Amount$0.66

Yield1.09%

Annual$2.46